Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Bullboard Posts
Post by Awesomeness1on Dec 02, 2010 1:00am
425 Views
Post# 17787680

Article from the hearld Sun ...

Article from the hearld Sun ...
/www.heraldsun.com.au/ipad-application/keeping-it-small-just-makes-sense/story-fn6bn4mv-1225964129948"> https://www.heraldsun.com.au/ipad-application/keeping-it-small-just-makes-sense/story-fn6bn4mv-1225964129948">
https://www.heraldsun.com.au/ipad-application/keeping-it-small-just-makes-sense/story-fn6bn4mv-1225964129948


"In a somewhat bizarre move that shows how the world has shrunk, asuccessful but underappreciated Canadian biotechnology company is aboutto also list on the Australian Securities Exchange.

Bioniche has agreat track record of developing and selling more than 60 animal healthproducts for companion animals, livestock and horses.

However,even that business has struggled to provide enough cash to fund thedevelopment of its breakthrough human bladder cancer drug Urocidin.

Australian-bornchief executive, Graeme McRae, said Urocidin's potential was so strongthat US healthcare company Endo Pharmaceuticals had signed a globallicence, development and supply agreement to help fund final phase threetests.

Bladder cancer is the fourth most common cancer in men andthe 11th in women and current treatments are old and have many sideeffects, which should provide a ready market for Urocidin.

The drug also shows significant promise in treating other cancers.

Graemesaid up to 20 million new shares are on offer in Canada and Australiato raise $30 million. Vets in both countries are being sent theprospectus."


Bullboard Posts